In order to facilitate access of ASMQ in Southeast Asia, a South-South technology transfer between Farmanginhos/Fiocruz in Brazil and Cipla Ltd in India, the agreement for which was signed in 2008, came to completion in 2010 with support and facilitation by DNDi.
This technology transfer for the artesunate-mefloquine fixed-dose combination was the first of its kind between a company in Brazil and one in India, and was even more unique in that it involved a transfer from a public entity, Farmanguinhos, to a private company, Cipla Ltd.

Successful transfer of technology necessitates true partnership, as it is more than just a question of offering acquired information. The Farmanguinhos- Cipla technology transfer required the alignment of procedures to Good Manufacturing Practices (GMP) to achieve similar and comparable products that meet international requirements in order to benefit patients in all endemic countries.

Thanks to this transfer, ASMQ was registered in India in 2011 and in Malaysia in 2012.

More on ASMQ